Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Bitcoin has fluctuated within a narrow range in recent sessions, reflecting investor caution in an uncertain macroeconomic ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

The S&P 500 and Nasdaq ended higher with boosts from gains in Nvidia and Eli Lilly, while the Dow dipped slightly after a ...

At 11:26 a.m. ET, the Dow Jones Industrial Average fell 75.92 points, or 0.17%, to 44,797.36, the S&P 500 gained 14.66 points ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Wall Street drifted through a mixed day of trading as rising fashion and cigarette stocks worked against drops for Ford Motor ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

In early trading on Thursday, the Dow Jones Industrial Average rose 8.51 points, or 0.04 per cent, to 44,892.21, the S&P 500 ...

Under Armour (NYSE: UAA) (NYSE: UA) stock soared 8.3% after the sportswear retailer raised its forecast for annual profit, as its efforts to dial down on discounts coupled with easing product and ...